US-EU Index Rebalances / Quantitative Researcher, ORTEX

Dimitris Ioannidis

US-EU Index Rebalances / Quantitative Researcher

Global Financial Data and Analytics Platform

ORTEX

ORTEX is a global financial data and analytics platform providing real-time securities lending and short interest data, index rebalance data, holdings and insider transactions, trading signals, corporate actions and news,  stock machine learning and factor scores and other analytics. The majority of the data are downloadable and accessible through APIs.

Index Rebalance

<ul>
<li>
<a href="https://www.smartkarma.com/entities/jyong-biotech-ltd" target="_blank" data-smartkarma-citation="entities:46006:1" rel="noopener">Jyong Biotech (MENS US)</a> went public on 17 June 2025 on Nasdaq and has since skyrocketed by more than 400%, reaching a market cap of  ~$3bn.</li>
<li>Exclusion from US indices is expected due to ineligible index nationality.</li>
<li>Exclusion from Global indices is projected due to failing market cap and foreign listing eligibility.</li>
</ul>



Jyong Biotech (MENS US) went public on 17 June 2025 on Nasdaq and has since skyrocketed by more than 400%, reaching a market cap of  ~$3bn.
Exclusion from US indices is expected due to ineligible index nationality.
Exclusion from Global indices is projected due to failing market cap and foreign listing eligibility.


Jyong Biotech (MENS US): Taiwan-Based, US-Listed, Excluded from US & Global Indices

United States

Jyong Biotech Ltd. is a science-driven biotechnology company. The Company develops and markets plant-derived drugs for the treatment of urinary system diseases. Jyong Biotech operates worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jyong Biotech (MENS US): Taiwan-Based, US-Listed, Excluded from US & Global Indices

Jyong Biotech went public on Nasdaq in June 2025, soaring over 400% to a ~$3bn market cap, yet is set to be excluded from US and Global indices due...

Dimitris Ioannidis